Skip Navigation


Annals of Oncology Advance Access originally published online on November 30, 2005
Annals of Oncology 2006 17(3):381-390; doi:10.1093/annonc/mdj101
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/3/381    most recent
mdj101v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Neyt, M.
Right arrow Articles by Cocquyt, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neyt, M.
Right arrow Articles by Cocquyt, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial

M. Neyt1,*, J. Albrecht1 and V. Cocquyt2

1 Faculty of Economics and Business Administration, Department of Economics, Ghent University, Ghent; 2 Faculty of Medicine and Health Sciences, Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium

* Correspondence to: M. Neyt, Ghent University, Hoveniersberg 24, 9000 Ghent, Belgium. Tel: +32-9-264-4209; Fax: +32-9-264-3599; E-mail: mattias.neyt{at}ugent.be

Background: Herceptin® (trastuzumab) is a humanized monoclonal antibody that is being tested in the adjuvant setting. Cost implications of using trastuzumab, as administered in the Breast Cancer International Research Group 006 trial, are being calculated. This provides information on the treatment's value for money.

Methods: Standard breast cancer treatment models were set up for different subpopulations according to stage (I, II, III) and menopausal condition (<50 and >50 years). Costs were calculated from the hospital's point of view, using the micro-costing method. Life expectancy data were based on literature. Our comparator was the existing practice. In addition to a sensitivity analysis, a threshold analysis on the prices of trastuzumab and docetaxel was performed to target an acceptable incremental cost-effectiveness ratio.

Results: Treatment costs were {euro}45 034 (doxorubicin and cyclophosphamide -> docetaxel and trastuzumab) or {euro}47 765 (docetaxel, carboplatin and trastuzumab). This was largely (79% and 75%, respectively) attributed to trastuzumab. According to our threshold analysis, an acceptable incremental cost-effectiveness ratio can be reached if health improvements are large enough and/or price discounts are given.

Conclusions: Trastuzumab is a promising but very expensive antibody. With the current pressure on health-care budgets, cost implications of using trastuzumab in adjuvant setting must be calculated before use of the product becomes wide-spread. This provides essential information for price-setting policies and for policy makers considering reimbursement.

Key words: breast cancer, cost-effectiveness, Herceptin®, threshold analysis, treatment model


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JRSMHome page
R. MacKenzie, S. Chapman, G. Salkeld, and S. Holding
Media influence on Herceptin subsidization in Australia: application of the rule of rescue?
J R Soc Med, June 1, 2008; 101(6): 305 - 312.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. A.M.S. van Dongen, G. W.M. Visser, M. N. Lub-de Hooge, E. G. de Vries, and L. R. Perk
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
Oncologist, December 1, 2007; 12(12): 1379 - 1389.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Dedes, T. Szucs, P Imesch, A Fedier, M. Fehr, and D Fink
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
Ann. Onc., September 1, 2007; 18(9): 1493 - 1499.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Beauclair, P Formento, J. Fischel, W Lescaut, R Largillier, E Chamorey, P Hofman, J. Ferrero, G Pages, and G Milano
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
Ann. Onc., August 1, 2007; 18(8): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. L. Liberato, M. Marchetti, and G. Barosi
Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
J. Clin. Oncol., February 20, 2007; 25(6): 625 - 633.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Gianni
The cost of life: should it matter to doctors?
Ann. Onc., March 1, 2006; 17(3): 357 - 358.
[Full Text] [PDF]

Home page
 BMJHome page
T. Juniper
Global warming must be limited to 2{degrees}C, scientists say
BMJ, December 3, 2005; 331(7528): 1287 - 1287.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.